论文部分内容阅读
目的:从中医证候的改善情况以及治疗后复发率了解宁肺丸治疗咳嗽变异性哮喘(cough variant asthm a,CVA)的临床疗效。方法:本文采用随机对照临床试验,共纳入对皮肤尘螨过敏试验(++~++++)的CVA患者138例,随机分为研究组三组。研究组A的患者接受宁肺丸、必可酮、特异性脱敏疗法(spec ific immun ity treatm ent,SIT)治疗方案;研究组B接受宁肺丸、必可酮治疗方案;对照组接受必可酮治疗方案。每组疗程3月。观察治疗前及治疗3个月后的中医证候及1年后的复发率。结果:治疗前后积分差值在研究组A与研究组B、对照组之间比较均具有统计学意义(P<0.05)。研究组A的总显效率及总有效率明显高于其它两组(P<0.05),研究组B的总有效率明显高于对照组(P<0.05)。1年后研究组A、研究组B、对照组的复发率分别为46.5%、63.6%、74.4%。结论:必可酮联合宁肺丸治疗方案可提高尘螨过敏的CVA患者临床疗效,降低其复发率,若再联合SIT,可进一步提高其临床疗效及降低复发率,甚至可以达到临床治愈。
Objective: To investigate the clinical effect of Ningfei Pill on cough variant asthma (CVA) based on the improvement of TCM syndromes and the relapse rate after treatment. Methods: A randomized controlled clinical trial was conducted in which 138 patients with CVA who were allergic to skin dust mite (++ ~ ++++) were randomly divided into three groups. Patients in study group A received nifedipine, ketoconazole, and specific immunosuppressive therapy (SIT); study group B received nifedipine and becidone; and those in control group received Can ketone treatment options. Each course of treatment in March. Observed before treatment and after 3 months of treatment of Chinese medicine and 1 year after the recurrence rate. Results: Before and after treatment, the difference between the scores in study group A and study group B and control group were statistically significant (P <0.05). The total effective rate and total effective rate of study group A were significantly higher than those of the other two groups (P <0.05). The total effective rate of study group B was significantly higher than that of the control group (P <0.05). One year later, the recurrence rates of study group A, study group B and control group were 46.5%, 63.6% and 74.4% respectively. Conclusion: The combination of bixodone and ningfei pills can improve the clinical efficacy and reduce the recurrence rate of CVA patients with dust mite allergy. Combined with SIT, the clinical efficacy and the relapse rate of CVB can be further improved and even clinical cure can be achieved.